Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
13 Setembro 2022 - 9:30AM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announces the appointment of Gerard
DiGirolamo as National Sales Director. In this newly created
position, Mr. DiGirolamo will report to Mark Baldyga, Biofrontera’s
Head of Sales & Marketing, and will help execute the Company’s
U.S. sales division and objectives including the strategic design,
expansion and leadership of its sales team. He will oversee
recruiting and staffing to support Ameluz®, BF-RhodoLED® and Xepi®
commercial efforts, as well as spearhead planning for the launch of
BF-RhodoLED XL®.
Mr. DiGirolamo brings to Biofrontera more than
25 years of experience in building pharmaceutical sales and
commercial teams with a particular expertise in dermatology. Most
recently he served as Vice President of Sales at Verrica
Pharmaceuticals, a medical dermatology company where he built their
U.S. sales infrastructure in preparation for a commercial launch of
its drug-device combination product for the treatment of molluscum
contagiosum. This provides valuable experience for working with
Biofrontera’s combination of Ameluz® and the RhodoLED® lamps.
“Gerard’s insight and understanding of the
dermatology market, along with the many relationships he’s
cultivated within our industry will be extremely valuable in
working with Mark Baldyga on the successful implementation of our
commercial strategy. His approach involving collaborating with
medical affairs, marketing, key opinion leaders and national
influencers through advisory boards and conferences fully aligns
with our mission. He is passionate about building cohesive and
collaborative teams that have led to successful product launches
and market-share gains. We are delighted to have Gerard lead our
commercial team and welcome him to Biofrontera,” stated Erica
Monaco, Chief Executive Officer of Biofrontera Inc.
“I’m proud to join Biofrontera and to support
their commitment to dermatological innovation. With my experience
in building and supporting teams at national and regional levels, I
look forward to leveraging my networks to position Ameluz-PDT as
the first-choice treatment for actinic keratosis and establishing
the optimal commercial infrastructure for a successful launch of
BF-RhodoLED XL®,” stated Mr. DiGirolamo.
Prior to Verrica Pharmaceuticals, Mr. DiGirolamo
was a Field Vice President at GlaxoSmithKline (GSK) and previously
spent 16 years with Stiefel, now part of GSK. At GSK he worked with
multiple dermatology brands and exceeded sales forecasts including
for the launch of Fabior Foam®, a treatment for psoriasis and acne.
As Executive National Account Manager at Stiefel he led
negotiations with national managed care organizations, securing
unrestricted access to the acne therapy Duac CS™ and coverage of
the seborrheic dermatitis therapies Extina™ and Xologel™. Prior to
Stiefel, he was an Area and District Sales Manager at Novartis. Mr.
DiGirolamo holds a B.A. from Rutgers University.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical
antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin
lesions, as well as impetigo, a bacterial skin infection. For more
information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may
constitute "forward-looking statements" within the meaning of the
United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to,
statements relating to the Company’s business and marketing
strategy, future operations and business, potential to expand the
label of Ameluz®, market presence and position of Ameluz® and
ongoing clinical trials conducted by our licensing partners and the
future impact of such trials on the market for Ameluz®. We have
based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results
or events could differ materially from the plans, intentions and
expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which
are beyond our control, including, but not limited to, the impact
of extraordinary external events, such as the current COVID-19
pandemic; any changes in the Company’s relationship with its
licensors; the ability of the Company’s licensors to fulfill their
obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current
global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in
the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the
Company’s licensed products; the uncertainties inherent in the
initiation and conduct of clinical trials; availability and timing
of data from clinical trials; whether results of earlier clinical
trials or trials of Ameluz® in combination with BF-RhodoLED® in
different disease indications or product applications will be
indicative of the results of ongoing or future trials;
uncertainties associated with regulatory review of clinical trials
and applications for marketing approvals; whether the market
opportunity for Ameluz® in combination with BF-RhodoLED® is
consistent with the Company’s expectations; the Company’s ability
to complete the transition to a public company; the Company’s
ability to retain and hire key personnel; the sufficiency of cash
resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can
be obtained on the SEC website at www.sec.gov. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management's current estimates, projections,
expectations and beliefs. The Company does not plan to update any
such forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Contacts:
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Biofrontera (NASDAQ:BFRIW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024